Difference between revisions of "From Review Papers"
imported>조우빈 |
imported>조우빈 |
||
Line 50: | Line 50: | ||
<p> </p> | <p> </p> | ||
+ | |||
+ | <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/27140638">https://www.ncbi.nlm.nih.gov/pubmed/27140638</a></p> | ||
+ | |||
+ | <p>(Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles.)</p> | ||
+ | |||
+ | <p>*Rosi ->PPAR activity increase</p> | ||
+ | |||
+ | <p>(1)Expression of uncoupling protein(UCP1) increase</p> | ||
+ | |||
+ | <p>-> Transformation (WAT->Brown-like adipose tissue) & Angiogenesis increase</p> | ||
+ | |||
+ | <p>(2) Expression of VEGF& Angiopoietin-like 4 increase</p> | ||
+ | |||
+ | <p>-> Adipose tissue angiogenesis increase</p> | ||
+ | |||
+ | <p>*PGE2(Prostaglandin E2)</p> | ||
+ | |||
+ | <p>-> Activate Prostaglandin receptor -> UCP1 Expression increase ->Adipose tissue transformation increase </p> | ||
+ | |||
+ | <p>*Increased Angiogenesis</p> | ||
+ | |||
+ | <p>=> Mobility of Targeted NPs to Adipose angiogenic vessel increase(Efficiency increase)</p> | ||
<p> </p> | <p> </p> |
Revision as of 13:45, 4 December 2016
http://www.nature.com/nature/journal/v537/n7620/pdf/nature19949.pdf
(Mass-Spectrometric exploration of proteome structure and function)
-> Provide unprecedented insights into the composition, structure, function and control of the proteome, shedding light on complex biological processes and phenotypes.
- Mass-Spectrometry-based methods
https://www.ncbi.nlm.nih.gov/pubmed/12634792
(From genomics to proteomics.)
- Proteomics would not be possible without the previous achievements of genomics, which provided the ‘blueprint’
of possible gene products that are the focal point of proteomics studies.
- The ability of mass spectrometry to identify ever smaller amounts of protein from increasingly complex mixtures is a
primary driving force in proteomics, as described in the review on page 198 by Aebersold and Mann.
Proteomics is set to have a profound impact on clinical diagnosis and drug discovery, as is fittingly reviewed by Sam Hanash on page 226, the inaugural president of HUPO.
Because most drug targets are proteins, it is inescapable that proteomics will enable drug discovery, development and clinical practice.
https://www.ncbi.nlm.nih.gov/pubmed/?term=metabolomics%3A+the+apogee+of
(Innovation: Metabolomics: the apogee of the omics trilogy.)
- metabolites serve as direct signatures of biochemical activity and are therefore easier to correlate with phenotype.
- metabolites serve as direct signatures of biochemical activity
- The untargeted [metabolomic] workflow is global in scope and outputs data related to comprehensive cellular metabolism.
- In particular, it has been useful in identifying altered metabolic pathways in disease that represent novel drug targets: an evolving biomedical application referred to as ‘therapeutic metabolomics’
- Another area is in characterizing gene and protein function. In addition to successfully identifying the function of unknown genes and proteins, untargeted profiling has been applied to discover new functions for known genes and proteins.
https://www.ncbi.nlm.nih.gov/pubmed/27140638
(Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles.)
*Rosi ->PPAR activity increase
(1)Expression of uncoupling protein(UCP1) increase
-> Transformation (WAT->Brown-like adipose tissue) & Angiogenesis increase
(2) Expression of VEGF& Angiopoietin-like 4 increase
-> Adipose tissue angiogenesis increase
*PGE2(Prostaglandin E2)
-> Activate Prostaglandin receptor -> UCP1 Expression increase ->Adipose tissue transformation increase
*Increased Angiogenesis
=> Mobility of Targeted NPs to Adipose angiogenic vessel increase(Efficiency increase)
----------------------------------------------